Search
Diphenoxylate
go.drugbank.com/drugs/DB01081ApprovedIllicitInvestigationalThis medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.
Polydatin
go.drugbank.com/drugs/DB11263ApprovedIt is shown to mediate a cytotoxic action on colorectal cancer cells by inducing cell arrest and apoptosis [A27229].
Rice bran oil
go.drugbank.com/drugs/DB11293ApprovedInvestigationalRice bran oil is classified as an indirect additive used in food contact substances by the FDA.
Dactinomycin
go.drugbank.com/drugs/DB00970ApprovedInvestigationalA compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termina...
Synonyms: ONCOSTATIN KProducts: K. U. DACTINOMYCIN FOR INJECTION 0.5 mg/vialCorticosterone
go.drugbank.com/drugs/DB04652InvestigationalAn adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.
Sirna-027
go.drugbank.com/drugs/DB05896InvestigationalSirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular degeneration.
Nitroprusside
go.drugbank.com/drugs/DB00325ApprovedInvestigationalNitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing...
Oteseconazole
go.drugbank.com/drugs/DB13055ApprovedInvestigational[L41635] This drug was approved by the FDA on April 26, 2022.[L41645] … [L41635,A247020] By binding and inhibiting CYP51, oteseconazole is active against most microorganisms associated with recurrent vulvovaginal candidiasis (RVVC).
Motexafin gadolinium
go.drugbank.com/drugs/DB05428InvestigationalMotexafin gadolinium is studied in the treatment of cancer by Pharmacyclics.
Axitinib
go.drugbank.com/drugs/DB06626ApprovedInvestigationalAxitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).